Ipsen announces its intention to acquire ImCheck Therapeutics

On October 22, 2025, the biopharmaceutical group Ipsen announced that it had entered into a definitive agreement to acquire ImCheck Therapeutics, a biotechnology company specializing in the design and development of a new generation of immunotherapeutic antibodies targeting butyrophilins.

A global player committed to developing innovative medicines for patients in three major therapeutic areas—Oncology, Rare Diseases, and Neuroscience—Ipsen expects to finalize this transaction by the end of the first quarter of 2026, subject to customary closing conditions, including obtaining the necessary regulatory approvals in France and the United States.

This strategic acquisition will enable Ipsen to strengthen its oncology research and development portfolio, with the aim of offering increasingly innovative treatments to patients.

Plasseraud IP has been advising these leading players for several years:

• Denis Bourgarel, Partner and Head of the Life Sciences Patent Practice, has been advising ImCheck Therapeutics on its industrial property strategy and patent management since its creation.
• Nathalie Wajs, Partner and Head of the Chemistry Patent Practice, has been assisting Ipsen in its opposition proceedings before the European Patent Office (EPO).